OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in oncology
2021;11 757403.

Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review.

Chao Chen, Wei Zhang, Daobin Zhou, Yan Zhang
Author Information
  1. Chao Chen: Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences (CAMS), Beijing, China.
  2. Wei Zhang: Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences (CAMS), Beijing, China.
  3. Daobin Zhou: Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences (CAMS), Beijing, China.
  4. Yan Zhang: Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences (CAMS), Beijing, China.
PMID: 34820328 DOI: 10.3389/fonc.2021.757403

Abstract

Patients with relapsed/refractory (R/R) transformed diffused Large B Cell Lymphoma (tDLBCL) have a poor prognosis and a low survival rate. In addition, no standard therapy has yet been established for R/R tDLBCL. Herein we presented a single case of a patient with R/R tDLBCL who was successfully treated with Sintilimab and chidamide. The patient was a 71-year-old man with pulmonary mucosa-associated lymphoid tissue lymphoma. He did not receive any treatment until tDLBCL was confirmed 2 years later. The tDLBCL was primary refractory to R2-CHOP, R2-MTX, and Gemox regimens. However, the patient achieved sustained complete remission after the combination therapy of Sintilimab and chidamide. To the best of our knowledge, this is the first report of Sintilimab combined with chidamide for the treatment of R/R tDLBCL, which opens up new therapeutic possibilities for this new combination therapy in future prospective clinical trials.

Keywords

HDAC inhibitor anti-PD-1 histologic transformation refractory transformed diffuse large B cell lymphoma

References

  1. Blood. 2017 Oct 19;130(16):1800-1808 [PMID: 28774879]
  2. Br J Haematol. 2020 Jun;189(6):1119-1126 [PMID: 32030732]
  3. Pathol Oncol Res. 2017 Apr;23(2):225-234 [PMID: 27722982]
  4. Cancer Chemother Pharmacol. 2012 Apr;69(4):901-9 [PMID: 22080169]
  5. Sci Transl Med. 2016 Nov 9;8(364):364ra155 [PMID: 27831904]
  6. Cancer Immunol Immunother. 2021 Jan;70(1):61-73 [PMID: 32632663]
  7. Front Oncol. 2020 May 15;10:699 [PMID: 32500025]
  8. Hematology Am Soc Hematol Educ Program. 2015;2015:625-30 [PMID: 26637780]
  9. Blood. 2017 Apr 6;129(14):1947-1957 [PMID: 28096087]
  10. Sci Rep. 2019 Apr 16;9(1):6136 [PMID: 30992475]
  11. Nat Rev Cancer. 2017 Apr;17(4):223-238 [PMID: 28233803]
  12. Front Oncol. 2020 Dec 11;10:608304 [PMID: 33363038]
  13. Cancer Discov. 2018 Nov;8(11):1422-1437 [PMID: 30181244]
  14. Br J Haematol. 2011 Aug;154(4):477-81 [PMID: 21707581]
  15. Clin Cancer Res. 2020 Feb 15;26(4):837-845 [PMID: 31796519]
  16. Cancer Discov. 2020 Mar;10(3):440-459 [PMID: 31915197]
  17. Front Pharmacol. 2019 May 01;10:387 [PMID: 31118893]
  18. Cancer Immunol Immunother. 2019 Mar;68(3):379-393 [PMID: 30547218]
  19. Clin Cancer Res. 2019 Jan 15;25(2):735-746 [PMID: 30348636]
  20. Comput Struct Biotechnol J. 2019 May 23;17:661-674 [PMID: 31205619]
  21. Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):122-137 [PMID: 31265877]
  22. Best Pract Res Clin Haematol. 2017 Mar - Jun;30(1-2):131-138 [PMID: 28288708]
  23. Nat Rev Clin Oncol. 2020 Dec;17(12):757-770 [PMID: 32632268]
  24. Cancer Immunol Immunother. 2019 Jun;68(6):983-990 [PMID: 30993371]
  25. Cell. 2017 Feb 9;168(4):571-574 [PMID: 28187279]
  26. Sci Rep. 2017 May 23;7(1):2290 [PMID: 28536458]
  27. N Engl J Med. 2018 Nov 01;379(18):1754-1765 [PMID: 30380390]
  28. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):176-181 [PMID: 33358575]
  29. Mol Cancer. 2018 Aug 23;17(1):129 [PMID: 30139382]
  30. Acta Pharm Sin B. 2020 May;10(5):723-733 [PMID: 32528824]
  31. J Clin Oncol. 2019 Feb 20;37(6):481-489 [PMID: 30620669]
  32. Leuk Lymphoma. 2016 Sep;57(9):2171-9 [PMID: 26883583]
  33. J Clin Oncol. 2018 Oct 12;:JCO1800138 [PMID: 30312133]
  34. Blood Cancer J. 2018 Aug 1;8(8):74 [PMID: 30069017]
  35. J Cancer. 2020 Apr 6;11(14):4059-4072 [PMID: 32368288]
  36. Lancet Oncol. 2015 May;16(5):541-9 [PMID: 25842160]
  37. Ann Hematol. 2014 Jun;93(6):1007-14 [PMID: 24414374]
  38. Annu Rev Genomics Hum Genet. 2019 Aug 31;20:413-432 [PMID: 30995147]
  39. Br J Haematol. 2017 Aug;178(3):434-441 [PMID: 28440559]
  40. Cancer. 2013 Feb 1;119(3):629-38 [PMID: 22893605]
  41. Oncotarget. 2017 May 17;8(47):83155-83170 [PMID: 29137331]
  42. Clin Cancer Res. 2019 Nov 15;25(22):6623-6632 [PMID: 31409616]
  43. Medicine (Baltimore). 2021 Mar 12;100(10):e24824 [PMID: 33725836]
  44. Ann Oncol. 2017 May 1;28(5):1064-1069 [PMID: 28327924]
  45. J Clin Oncol. 2018 Oct 1;36(28):2845-2853 [PMID: 30125215]
  46. Blood. 2016 Jul 14;128(2):185-94 [PMID: 27166360]
  47. Mol Med Rep. 2021 May;23(5): [PMID: 33649847]
Case Reports Journal Article
Article has an altmetric score of 6

Word Cloud

Created with Highcharts 10.0.0tDLBCLR/RBlymphomatherapypatientsintilimabchidamidetransformedlargecelltreatmentrefractorycombinationnewPatientsrelapsed/refractorydiffusedpoorprognosislowsurvivalrateadditionstandardyetestablishedHereinpresentedsinglecasesuccessfullytreated71-year-oldmanpulmonarymucosa-associatedlymphoidtissuereceiveconfirmed2yearslaterprimaryR2-CHOPR2-MTXGemoxregimensHoweverachievedsustainedcompleteremissionbestknowledgefirstreportcombinedopenstherapeuticpossibilitiesfutureprospectiveclinicaltrialsSintilimabChidamideRefractoryTransformedDiffuseLargeCellLymphoma:CaseReportLiteratureReviewHDACinhibitoranti-PD-1histologictransformationdiffuse

Similar Articles

Cited By (6)